Supriya Lifescience, a global pharmaceutical industry leader, has achieved two significant milestones, strengthening its position in international markets.

The company has acquired approval from Brazil's health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM (Latin America). Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialized pharmaceutical.

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.

Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya's dedication to drug cost and raising accessibility.

With CADIFA (certification for API quality) approval in place, Supriya Lifescience is now ready to tap into the fast- growing LATAM market.